TherapeuticsMD (TXMD) Research & Development (2011 - 2022)

TherapeuticsMD's Research & Development history runs 12 years deep, the most recent figure standing at $1.1 million for Q3 2022.

• Quarterly Research & Development fell 30.72% year-over-year to $1.1 million in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $23.0 million (down 72.54% YoY) and the FY2021 annual result came in at $7.1 million, down 93.95% from the prior year.
• Research & Development was $1.1 million for Q3 2022 at TherapeuticsMD, down from $1.6 million in the prior quarter.
• Across five years, Research & Development topped out at $98.9 million in Q4 2019 and bottomed at $1.1 million in Q3 2022.
• A 5-year average of $13.5 million and a median of $6.3 million in 2019 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2019 — Research & Development surged 1364.06% — and 2022, when it slumped 95.09%.
• TherapeuticsMD's Research & Development stood at $6.8 million in 2018, then jumped by 1364.06% to $98.9 million in 2019, then slumped by 73.71% to $26.0 million in 2020, then tumbled by 94.54% to $1.4 million in 2021, then fell by 21.69% to $1.1 million in 2022.
• Business Quant data shows TXMD's Research & Development at $1.1 million in Q3 2022, $1.6 million in Q2 2022, and $18.9 million in Q1 2022.